Abstract
Current literature gives evidence of an indisputable role adiponectin plays in adipose tissue metabolism and obesity-related diseases. Moreover, latest research efforts focus on linking genetic markers of this adipocytokine’s gene (ADIPOQ) with cancer. Aim of this study was to determine the genotype distribution of single nucleotide polymorphism +276G > T (rs1501299) in ADIPOQ and an attempt to identify the impact this polymorphism exerts on endometrial cancer risk in obese females. The test group comprised 90 women treated surgically for endometrial cancer between 2000 and 2012 in the Department of Surgical & Endoscopic Gynecology and Gynecologic Oncology, Polish Mothers’ Memorial Hospital - Research Institute, Lodz, Poland. 90 individuals treated in the parallel period for uterine fibroids constituted the control group. Patients within both groups were stratified according to BMI into: lean, overweight and obese subjects. Statistical analysis was performed between two major groups and, furthermore, within the abovementioned subgroups. The analysis revealed that allele G of the investigated polymorphism in obese women with endometrial cancer is significantly more frequent, and allele T is significantly less frequent than in lean controls. However, no significant correlation was observed between the polymorphism and endometrial cancer in lean and overweight females. Single nucleotide polymorphism +276G > T (rs1501299) in ADIPOQ may be considered to be a risk factor of endometrial cancer. Further research on SNP in EC is warranted to obtain more conclusive outcomes.
Similar content being viewed by others
References
Siegel R, Naishadham D, Jemal A, et al. (2012) Cancer statistics. CA Cancer J Clin 62(1):10–29
Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17
Crosbie EJ, Zwahlen M, Kitchener HC, et al. (2010) Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev 19(12):3119–3130
Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014 Aug 30;384(9945):755–765.
SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, et al. (2014) Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol 134(2):385–392
Calle EE, Rodriguez C, Walker-Thurmond K, et al. (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638
Friberg E, Mantzoros CS, Wolk A (2007) Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomark Prev 16(2):276–280
Hecht J, Mutter GL (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24(29):4783–4791
Tilg H (2006) Moschen AR adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6(10):772–783
Nigro E, Scudiero O, Monaco ML, et al. (2014) New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int 2014:658913
Fisman EZ, Tenenbaum A (2014) Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary Disease? Cardiovasc Diabetol 13:103
Di Chiara T, Argano C, Corrao S, et al. (2012) Hypoadiponectinemia: a link between visceral obesity and metabolic syndrome. J Nutr Metab 2012:175245
Chandran M, Phillips SA, Ciaraldi T, et al. (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26(8):2442–2450
Gu HF (2009) Biomarkers of adiponectin: plasma protein variation and genomic DNA polymorphisms. Biomark Insights 4:123–133
Melistas L, Mantzoros CS, Kontogianni M, et al. (2009) Association of the +45 T > G and +276G > T polymorphisms in the adiponectin gene with insulin resistance in nondiabetic Greek women. Eur J Endocrinol 161(6):845–852
Stumvoll M, Tschritter O, Fritsche A, et al. (2002) Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 51(1):37–41
Chu H, Wang M, Zhong D, et al. (2013) AdipoQ polymorphisms are associated with type 2 diabetes mellitus: a meta-analysis study. Diabetes Metab Res Rev 29(7):532–545
Teras LR, Goodman M, Patel AV, et al. (2009) No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomark Prev 18(9):2553–2557
Ye C, Wang J, Tan, et al. (2013) Meta-analysis of adiponectin polymorphisms and colorectal cancer risk. Int J Med Sci 10(9):1113–1120
Dhillon PK, Penney KL, Schumacher F, et al. (2011) Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomark Prev 20(12):2618–2627
Chen X, Xiang YB, Long JR, et al. (2012) Genetic polymorphisms in obesity-related genes and endometrial cancer risk. Cancer 118(13):3356–3364
Meyer LA, Westin SN, Lu KH, et al. (2008) Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther 8(7):1159–1167
Fan HJ, Wen ZF, Xu BL, et al. (2013) Three adiponectin rs1501299G/T, rs822395A/C, and rs822396A/G polymorphisms and risk of cancer development: a meta-analysis. Tumour Biol 34(2):769–778
Conflict of Interest
We declare that we have no conflict of interest.
Authors' Contribution
Jan Bieńkiewicz: protocol and project development, data collection and management, manuscript writing and editing.
Beata Smolarz: genetical assays and data analysis.
Andrzej Malinowski: protocol and project development.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bieńkiewicz, J., Smolarz, B. & Malinowski, A. Association Between Single Nucleotide Polymorphism +276G > T (rs1501299) in ADIPOQ and Endometrial Cancer. Pathol. Oncol. Res. 22, 135–138 (2016). https://doi.org/10.1007/s12253-015-9985-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-015-9985-9